BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 8342564)

  • 1. Adoptive chemoimmunotherapy using ex vivo activated memory T-cells and cyclophosphamide: tumor lysis syndrome of a metastatic soft tissue sarcoma.
    Gold JE; Malamud SC; LaRosa F; Osband ME
    Am J Hematol; 1993 Sep; 44(1):42-7. PubMed ID: 8342564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adoptive chemoimmunotherapy for the treatment of relapsed and refractory solid tumors using ex vivo activated memory T cells (autolymphocyte therapy) and cyclophosphamide.
    Gold JE; Malamud SC; LaRosa F; Seder R; Osband ME
    J Immunother Emphasis Tumor Immunol; 1993 Apr; 13(3):213-21. PubMed ID: 8471596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptively transferred ex vivo activated memory T cells with cyclophosphamide: effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
    Gold JE; Zachary DT; Osband ME
    Clin Immunol Immunopathol; 1994 Oct; 73(1):115-22. PubMed ID: 7923908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
    Gold JE; Zachary DT; Osband ME
    Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ex vivo activated memory T-lymphocytes as adoptive cellular therapy of human soft-tissue sarcoma targets with potentiation by cis-diamminedichloroplatinum(II).
    Gold JE; Masters TR; Bloom ND; Shafir MK; Klein MJ; Kenan S; Osband ME
    J Surg Oncol; 1995 Apr; 58(4):212-21. PubMed ID: 7723363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adoptive transfer of ex vivo activated memory T-cells with or without cyclophosphamide for advanced metastatic melanoma: results in 36 patients.
    Gold JE; Ross SD; Krellenstein DJ; LaRosa F; Malamud SC; Osband ME
    Eur J Cancer; 1995; 31A(5):698-708. PubMed ID: 7640041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autolymphocyte therapy. II. Dependence of in vivo anti-tumor specificity and long-term immunity against murine melanoma and carcinoma on ex vivo activated donor memory T-cells.
    Gold JE; Osband ME
    Clin Immunol Immunopathol; 1994 Jun; 71(3):325-32. PubMed ID: 7911078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptive cellular therapy of human breast and colorectal tumor targets using ex vivo activated memory T lymphocytes with potentiation by cis-diamminedichloroplatinum(II).
    Gold JE; Bleiweiss IJ; Goldfarb AB; Bauer JJ; Gelernt IM; Schwartz ME; Reiner MA; Miller CM; Weiss MF; Brower ST
    J Surg Oncol; 1994 Apr; 55(4):222-8. PubMed ID: 8159004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autolymphocyte therapy. III. Effective adjuvant adoptive cellular therapy with in vivo anti-tumor specificity against murine melanoma and carcinoma using ex-vivo-activated memory T-lymphocytes.
    Gold JE; Masters TR; Osband ME
    J Surg Res; 1995 Aug; 59(2):279-86. PubMed ID: 7543632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ex vivo activated memory T-lymphocytes as adoptive cellular therapy of human renal cell tumour targets with potentiation by cis-diamminedichloroplatinum(II).
    Gold JE; Masters TR; Babbit B; Fine EM; Weber HN; Unger PD; Leventhal I; Zippe CD; Osband ME
    Br J Urol; 1995 Jul; 76(1):115-22. PubMed ID: 7648042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute tumor lysis syndrome in solid tumors--a case report and review of the literature.
    Baeksgaard L; Sørensen JB
    Cancer Chemother Pharmacol; 2003 Mar; 51(3):187-92. PubMed ID: 12655435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autolymphocyte therapy--I. In vivo tumour-specific adoptive cellular therapy of murine melanoma and carcinoma using ex vivo activated memory T-lymphocytes.
    Gold JE; Osband ME
    Eur J Cancer; 1994; 30A(12):1871-82. PubMed ID: 7880620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor Lysis Syndrome due to Eribulin Administration for Metastatic Undifferentiated Pleomorphic Sarcoma of the Buttock.
    Tsuchie H; Miyakoshi N; Nagasawa H; Shimada Y
    Acta Med Okayama; 2021 Aug; 75(4):533-538. PubMed ID: 34511623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case of tumor lysis syndrome following chemotherapy for a uterine epithelioid leiomyosarcoma with focal rhabdomyosarcomatous differentiation.
    Hiraizumi Y; Kamoi S; Inde Y; Kurose K; Ohaki Y; Takeshita T
    J Obstet Gynaecol Res; 2011 Jul; 37(7):947-52. PubMed ID: 21410837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of ex vivo-activated memory T cells (autolymphocyte therapy) in the treatment of metastatic renal cell carcinoma: final results from a randomized, controlled, multisite study.
    Graham S; Babayan RK; Lamm DL; Sawczuk I; Ross SD; Lavin PT; Osband ME; Krane RJ
    Semin Urol; 1993 Feb; 11(1):27-34. PubMed ID: 8465126
    [No Abstract]   [Full Text] [Related]  

  • 16. The therapeutic efficacy of murine anti-tumor T cells: freshly isolated T cells are more therapeutic than T cells expanded in vitro.
    Evans R; Kamdar SJ; Duffy TM; Krupke DM; Fuller JA; Dudley ME
    Anticancer Res; 1995; 15(2):441-7. PubMed ID: 7763019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined therapy in the treatment of gastric epithelioid leiomyosarcoma.
    van der Vaart CH; Spoelstra P; Samsom JP; Klinkert P; de Koning J
    Neth J Med; 1990 Feb; 36(1-2):69-73. PubMed ID: 2314523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour lysis syndrome: implications for cancer therapy.
    Mika D; Ahmad S; Guruvayoorappan C
    Asian Pac J Cancer Prev; 2012; 13(8):3555-60. PubMed ID: 23098434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase.
    Hummel M; Buchheidt D; Reiter S; Bergmann J; Adam K; Hehlmann R
    Eur J Haematol; 2005 Dec; 75(6):518-21. PubMed ID: 16313266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes.
    Chin CS; Miller CH; Graham L; Parviz M; Zacur S; Patel B; Duong A; Bear HD
    Int Immunol; 2004 Sep; 16(9):1283-94. PubMed ID: 15262898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.